Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Capital Expenditure | ($528.8M) | ($737.4M) | ($557.3M) | ($445.7M) | ($402.1M) | ($572.6M) | ($692.4M) | ($620.9M) | ($623.9M) | ($647.6M) | ($772.0M) | ($953.1M) | ($1,228.1M) | ($1,312.1M) | ($1,964.9M) | ($1,681.9M) | ($3,377.3M) | ($1,173.7M) | ($2,086.7M) | ($5,637.6M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Capital Expenditure is ($7,379.7M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Capital Expenditure growth was 80.1%. The average annual Capital Expenditure growth rates for Novo Nordisk A/S have been 29.2% over the past three years, 31.9% over the past five years.
Over the last year, Novo Nordisk A/S's Capital Expenditure growth was 80.1%, which is higher than industry growth of (0.6%). It indicates that Novo Nordisk A/S's Capital Expenditure growth is Bad.